Michelle M Kim1, Sandra Camelo-Piragua2, Matthew Schipper3, Yebin Tao3, Daniel Normolle4, Larry Junck5, Aaron Mammoser5, Bryan L Betz2, Yue Cao6, Christopher J Kim7, Jason Heth8, Oren Sagher8, Theodore S Lawrence7, Christina I Tsien9. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: michekim@med.umich.edu. 2. Department of Pathology, University of Michigan, Ann Arbor, Michigan. 3. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan. 4. Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Neurology, University of Michigan, Ann Arbor, Michigan. 6. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiology, University of Michigan, Ann Arbor, Michigan; Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan. 7. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 8. Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan. 9. Department of Radiation Oncology, Washington University, St. Louis, Missouri.
Abstract
PURPOSE: To evaluate the tolerability and efficacy of gemcitabine plus radiation therapy (RT) in this phase 1 study of patients with newly diagnosed malignant glioma (HGG). PATIENTS AND METHODS: Between 2004 and 2012, 29 adults with HGG were enrolled. After any extent of resection, RT (60 Gy over 6 weeks) was given concurrent with escalating doses of weekly gemcitabine. Using a time-to-event continual reassessment method, 5 dose levels were evaluated starting at 500 mg/m(2) during the last 2 weeks of RT and advanced stepwise into earlier weeks. The primary objective was to determine the recommended phase 2 dose of gemcitabine plus RT. Secondary objectives included progression-free survival, overall survival (OS), and long-term toxicity. RESULTS: Median follow-up was 38.1 months (range, 8.9-117.5 months); 24 patients were evaluable for toxicity. After 2005 when standard practice changed, patients with World Health Organization grade 4 tumors were no longer enrolled. Median progression-free survival for 22 patients with grade 3 tumors was 26.0 months (95% confidence interval [CI] 15.6-inestimable), and OS was 48.5 months (95% CI 26.8-inestimable). In 4 IDH mutated, 1p/19q codeleted patients, no failures occurred, with all but 1 alive at time of last follow-up. Seven with IDH mutated, non-codeleted tumors with ATRX loss had intermediate OS of 73.5 months (95% CI 32.8-inestimable). Six nonmutated, non-codeleted patients had a median OS of 26.5 months (95% CI 25.4-inestimable). The recommended phase 2 dose of gemcitabine plus RT was 750 mg/m(2)/wk given the last 4 weeks of RT. Dose reductions were most commonly due to grade 3 neutropenia; no grade 4 or 5 toxicities were seen. CONCLUSIONS: Gemcitabine concurrent with RT is well-tolerated and yields promising outcomes, including in patients with adverse molecular features. It is a candidate for further study, particularly for poor-prognosis patient subgroups with HGG. Published by Elsevier Inc.
PURPOSE: To evaluate the tolerability and efficacy of gemcitabine plus radiation therapy (RT) in this phase 1 study of patients with newly diagnosed malignant glioma (HGG). PATIENTS AND METHODS: Between 2004 and 2012, 29 adults with HGG were enrolled. After any extent of resection, RT (60 Gy over 6 weeks) was given concurrent with escalating doses of weekly gemcitabine. Using a time-to-event continual reassessment method, 5 dose levels were evaluated starting at 500 mg/m(2) during the last 2 weeks of RT and advanced stepwise into earlier weeks. The primary objective was to determine the recommended phase 2 dose of gemcitabine plus RT. Secondary objectives included progression-free survival, overall survival (OS), and long-term toxicity. RESULTS: Median follow-up was 38.1 months (range, 8.9-117.5 months); 24 patients were evaluable for toxicity. After 2005 when standard practice changed, patients with World Health Organization grade 4 tumors were no longer enrolled. Median progression-free survival for 22 patients with grade 3 tumors was 26.0 months (95% confidence interval [CI] 15.6-inestimable), and OS was 48.5 months (95% CI 26.8-inestimable). In 4 IDH mutated, 1p/19q codeleted patients, no failures occurred, with all but 1 alive at time of last follow-up. Seven with IDH mutated, non-codeleted tumors with ATRX loss had intermediate OS of 73.5 months (95% CI 32.8-inestimable). Six nonmutated, non-codeleted patients had a median OS of 26.5 months (95% CI 25.4-inestimable). The recommended phase 2 dose of gemcitabine plus RT was 750 mg/m(2)/wk given the last 4 weeks of RT. Dose reductions were most commonly due to grade 3 neutropenia; no grade 4 or 5 toxicities were seen. CONCLUSIONS:Gemcitabine concurrent with RT is well-tolerated and yields promising outcomes, including in patients with adverse molecular features. It is a candidate for further study, particularly for poor-prognosis patient subgroups with HGG. Published by Elsevier Inc.
Authors: Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Martin J van den Bent; Antoine F Carpentier; Alba A Brandes; Marc Sanson; Martin J B Taphoorn; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; Laslo Sipos; Hanny Haaxma-Reiche; Johannes M Kros; Mathilde C M van Kouwenhoven; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Lauren E Abrey; David N Louis; Nina Paleologos; Andrew B Lassman; Jeffrey J Raizer; Warren Mason; Jonathan Finlay; David R MacDonald; Lisa M DeAngelis; J Gregory Cairncross Journal: Neuro Oncol Date: 2007-04-13 Impact factor: 12.300
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: J Sigmond; R J Honeywell; T J Postma; C M F Dirven; S M de Lange; K van der Born; A C Laan; J C A Baayen; C J Van Groeningen; A M Bergman; G Giaccone; G J Peters Journal: Ann Oncol Date: 2008-08-12 Impact factor: 32.976
Authors: Elizabeth Kent; Howard Sandler; James Montie; Cheryl Lee; Joseph Herman; Peg Esper; Judith Fardig; David C Smith Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Daniel R Wahl; Joseph Dresser; Kari Wilder-Romans; Joshua D Parsels; Shuang G Zhao; Mary Davis; Lili Zhao; Maureen Kachman; Stefanie Wernisch; Charles F Burant; Meredith A Morgan; Felix Y Feng; Corey Speers; Costas A Lyssiotis; Theodore S Lawrence Journal: Cancer Res Date: 2016-12-06 Impact factor: 12.701
Authors: Sophie E M Veldhuijzen van Zanten; Fatma E El-Khouly; Marc H A Jansen; Dewi P Bakker; Esther Sanchez Aliaga; Cornelis J A Haasbeek; Nicole I Wolf; C Michel Zwaan; W Peter Vandertop; Dannis G van Vuurden; Gertjan J L Kaspers Journal: J Neurooncol Date: 2017-07-26 Impact factor: 4.130
Authors: Sean M Santos; Mert Icyuz; Ilya Pound; Doreen William; Jingyu Guo; Brett A McKinney; Michael Niederweis; John Rodgers; John L Hartman Journal: Genes (Basel) Date: 2019-09-30 Impact factor: 4.096
Authors: Sherise D Ferguson; Joanne Xiu; Shiao-Pei Weathers; Shouhao Zhou; Santosh Kesari; Stephanie E Weiss; Roeland G Verhaak; Raymond J Hohl; Geoffrey R Barger; Sandeep K Reddy; Amy B Heimberger Journal: Oncotarget Date: 2016-10-25